{
    "clinical_study": {
        "@rank": "146180", 
        "arm_group": [
            {
                "arm_group_label": "carboplatin chemotherapy", 
                "arm_group_type": "Experimental", 
                "description": "At the time of post neo-adjuvant period, the patients will be assigned to each treatment group in a 1:1 ratio i.e. carboplatin AUC 6 group vs. observation group. Six cycles of carboplatin (AUC=6) on the first day of every 21 days."
            }, 
            {
                "arm_group_label": "Observation arm", 
                "arm_group_type": "No Intervention", 
                "description": "In this observation arm, patients should be follow up with regular interval without treatment."
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to investigate the efficacy of carboplatin, as a post-operative\n      adjuvant chemotherapy for triple negative breast cancer patients who have pathologic\n      residual cancer after the preoperative chemotherapy."
        }, 
        "brief_title": "A Phase III Trial of Carboplatin as Adjuvant Chemotherapy in Triple Negative Breast Cancer", 
        "completion_date": {
            "#text": "March 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "In Neo-adjuvant period Four cycles of 60 mg/m2 doxorubicin and 600 mg/m2 cyclophosphamide\n      therapy at 3-week intervals followed by four cycles of 100 mg/m2 docetaxel at 3-week\n      intervals.\n\n      In POST Neo-adjuvant period\n\n      Randomization:\n\n      At the time of post neo-adjuvant period, the patients will be assigned to each treatment\n      group in a 1:1 ratio i.e. carboplatin AUC 6 group vs. observation group. Six cycles of\n      carboplatin (AUC=6) on the first day of every 21 days."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Clinical diagnosis of breast cancer\n\n               1. Female patients\n\n               2. Histologically confirmed invasive breast cancer\n\n                    1. Primary tumor greater than 2cm diameter, measured by mammography and\n                       sonography\n\n                    2. Any N\n\n               3. ER (estrogen receptor)/ PR (progesterone receptor) / HER2 (negative/ negative/\n                  negative)(ER <1%, PR<1%, IHC 0, 1+ or FISH - in case of IHC\n                  (immuno-histochemistry) 2+)\n\n               4. No evidence of metastasis (M0)\n\n               5. No prior hormonal, chemotherapy or radiotherapy is allowed.\n\n               6. No breast operation other than biopsy to make diagnosis is allowed.\n\n               7. Age: 20-years and older, not pregnant pre-, and postmenopausal women with good\n                  performance status (ECOG 0-1)\n\n               8. Adequate hematopoietic function: Absolute granulocyte count 1500/mm3, platelet\n                  100,000/mm3, Hemoglobin 10 g/mm3\n\n               9. Adequate renal function: Serum creatinine 1.5 mg/dl\n\n              10. Adequate hepatic function: total bilirubin: 1.5 mg/dl, AST(aspartate\n                  aminotransferase)/ALT (alanine transaminase): 2 times normal, Alkaline\n                  phosphatase:2 times normal\n\n              11. Written informed consent\n\n              12. Normal mental function to understand and sign the consent\n\n              13. Cardiac function: normal or nonspecific EKG taken within 1 mo of enrollment.\n\n              14. LVEF (left ventricular ejection fraction)50% by MUGA (multiple gated acquisition\n                  scan) or Echocardiogram taken within 1 mo of enrollment\n\n        Exclusion Criteria:\n\n          1. Patients who received hormonal, chemotherapy or radiotherapy for breast cancer\n\n          2. Patients who underwent surgery for breast cancer\n\n          3. Patients with a history of uncompensated congestive heart failure\n\n          4. Patients with inflammatory breast cancer (T4d)\n\n          5. Patients without primary tumor (T0)\n\n          6. Patients who have history of cancer other than in situ uterine cervix cancer or\n             non-melanotic skin cancer\n\n          7. Known hypersensitivity to any of the study drugs"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "587", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01752686", 
            "org_study_id": "Severance_BR_01", 
            "secondary_id": "DA-TNBC"
        }, 
        "intervention": {
            "arm_group_label": "carboplatin chemotherapy", 
            "description": "carboplatin as adjuvant chemotherapy", 
            "intervention_name": "carboplatin", 
            "intervention_type": "Drug", 
            "other_name": "Adding adjuvant arm"
        }, 
        "intervention_browse": {
            "mesh_term": "Carboplatin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Triple negative breast cancer", 
            "adjuvant chemotherapy"
        ], 
        "lastchanged_date": "December 21, 2012", 
        "number_of_arms": "2", 
        "official_title": "A Phase III Trial of Carboplatin as Adjuvant Chemotherapy Versus Observation in Triple Negative Breast Cancer With Pathologic Residual Cancer After Neoadjuvant Chemotherapy: POST-Neo Adjuvant Study", 
        "other_outcome": {
            "measure": "difference in gene expression pattern", 
            "safety_issue": "No", 
            "time_frame": "up to 5 years"
        }, 
        "overall_contact": {
            "email": "nobelg@yuhs.ac", 
            "last_name": "Byeong Woo Park, MD, PhD", 
            "phone": "82-2-2228-8125"
        }, 
        "overall_official": {
            "affiliation": "Severance Hospital", 
            "last_name": "Byeong Woo Park, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To compare DFS between carboplatin and observation within non-pCR (complete remission) patients", 
            "measure": "Disease-free survival (DFS)", 
            "safety_issue": "Yes", 
            "time_frame": "up to 3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01752686"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Severance Hospital", 
            "investigator_full_name": "Byeong Woo Park", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "To compare overall survival (OS) between carboplatin and observation within non-pCR patients.", 
                "measure": "overall survival", 
                "safety_issue": "Yes", 
                "time_frame": "up to 5years"
            }, 
            {
                "description": "To assess the pCR rate (no residual invasive carcinoma in primary breast and axillary lymph node) within total TNBC patients.", 
                "measure": "pCR rate", 
                "safety_issue": "Yes", 
                "time_frame": "up to 3 years"
            }, 
            {
                "description": "To assess the percentage of patients who receive breast conserving surgery within total triple negative breast cancer patients", 
                "measure": "The percentage of patients who receive breast conserving surgery.", 
                "safety_issue": "Yes", 
                "time_frame": "up to 3years"
            }, 
            {
                "description": "Number of adverse events in patients with non-pCR.", 
                "measure": "Number of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "up to 3years"
            }
        ], 
        "source": "Severance Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Severance Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}